{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T22:52:30Z","timestamp":1782946350171,"version":"3.54.5"},"reference-count":126,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Orphan drugs are used for the diagnosis, prevention and treatment of rare diseases that, in the European Union, are defined as disorders affecting no more than 5 persons in 10,000. So far, a total of around 800 orphan medicinal products have been approved by the European Medicines Agency, however the utilization profile of orphan drugs has yet to be explored. This study aimed at assessing the utilization profile of orphan drugs authorized for marketing by the Italian Medicines Agency using population-based data.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A total of 21 orphan drugs used in outpatient settings, approved in the European Union before or during the 2008\u20132018 period and involving 15 rare diseases, were included in the study. The monitored population included patients with one of the conditions surveilled by the population-based Tuscany Registry of Rare Diseases and diagnosed between 2000\u20132018. A multi-database approach was applied, by linking data from the registry with information collected in drug prescriptions databases. The prevalence and intensity of use were estimated for the selected orphan drugs and other non-orphan medications, used to treat the same rare disease and for which a change in the prevalence of use was hypothesized after authorization of the orphan drug.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> For some diseases (acquired aplastic anemia, tuberous sclerosis complex, most metabolic diseases) a low prevalence of orphan drugs use was observed (range between 1.1\u201312.5%). Conversely, orphan drugs were frequently used in hemophilia B, Wilson disease and idiopathic pulmonary fibrosis (maximum of 78.3, 47.6 and 41.8%, respectively). For hemophilia B and Leber\u2019s hereditary optic neuropathy, there are currently no other medications used in clinical practice in addition to orphan drugs. Six orphan drugs were used for the treatment of pulmonary arterial hypertension, appearing the elective therapy for this disease, albeit with different utilization profiles (range of prevalence 1.7\u201355.6%).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> To the best of our knowledge, this is the first study investigating the utilization profile of orphan drugs prescribed in a defined geographical area, and providing relevant information to monitor over time potential changes in the prevalence of these medications as well as in the health care decision making.<\/jats:p>","DOI":"10.3389\/fphar.2022.869842","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T04:44:04Z","timestamp":1652676244000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study"],"prefix":"10.3389","volume":"13","author":[{"given":"Francesca","family":"Gorini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pierini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Mezzasalma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Baldacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bargagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Boncristiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizia Rossana","family":"Brunetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cameli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Coco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alice","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Guerrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Linari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Murro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Parronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pochiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliviero","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Scappini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Maria","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Coi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.7916\/D841881D","article-title":"Advances in Treatment of Wilson Disease","volume":"8","author":"Aggarwal","year":"2018","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4103\/0973-6247.200768","article-title":"Comparison of Deferasirox and Deferoxamine Effects on Iron Overload and Immunological Changes in Patients with Blood Transfusion-dependent \u03b2-thalassemia","volume":"11","author":"Al-Kuraishy","year":"2017","journal-title":"Asian J. Transfus. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1111\/jth.12756","article-title":"Pharmacokinetic and Pharmacodynamic Properties of Plasma-Derived vs. Recombinant Factor IX in Patients with Hemophilia B: a Prospective Crossover Study","volume":"12","author":"Alamelu","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"B4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s13023-021-02032-8","article-title":"Long-term Effectiveness of Carglumic Acid in Patients with Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA): a Randomized Clinical Trial","volume":"16","author":"Alfadhel","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1111\/liv.14179","article-title":"Comparative Effectiveness of Common Therapies for Wilson Disease: A Systematic Review and Meta-Analysis of Controlled Studies","volume":"39","author":"Appenzeller-Herzog","year":"2019","journal-title":"Liver Int."},{"key":"B6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4274\/tjh.galenos.2019.2018.0393","article-title":"Extended Half-Life Coagulation Factors: A New Era in the Management of Hemophilia Patients","volume":"36","author":"Ar","year":"2019","journal-title":"Turk J. Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1182\/blood-2016-08-693481","article-title":"How I Treat Acquired Aplastic Anemia","volume":"129","author":"Bacigalupo","year":"2017","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.arbres.2017.11.014","article-title":"Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Summary of Recommendations","volume":"54","author":"Barber\u00e0","year":"2018","journal-title":"Arch. Bronconeumol (Engl Ed."},{"key":"B9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13023-014-0130-8","article-title":"Proposed Guidelines for the Diagnosis and Management of Methylmalonic and Propionic Acidemia","volume":"9","author":"Baumgartner","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1056\/NEJMc1207471","article-title":"Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis","volume":"367","author":"Behr","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1753466618823440","DOI":"10.1177\/1753466618823440","article-title":"Treatment of Pulmonary Arterial Hypertension with the Dual Endothelin Receptor Antagonist Macitentan: Clinical Evidence and Experience","volume":"13","author":"Belge","year":"2019","journal-title":"Ther. Adv. Respir. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejim.2016.07.011","article-title":"Management and Monitoring Recommendations for the Use of Eliglustat in Adults with Type 1 Gaucher Disease in Europe","volume":"37","author":"Belmatoug","year":"2017","journal-title":"Eur. J. Intern. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.bcmd.2016.10.008","article-title":"Management Goals for Type 1 Gaucher Disease: An Expert Consensus Document from the European Working Group on Gaucher Disease","volume":"68","author":"Biegstraaten","year":"2018","journal-title":"Blood Cell Mol. Dis."},{"key":"B14","volume-title":"Phenylketonuria and BH4 Deficiencies","author":"Blau","year":"2021"},{"key":"B15","doi-asserted-by":"publisher","first-page":"CD007476","DOI":"10.1002\/14651858.CD007476.pub3","article-title":"Deferasirox for Managing Iron Overload in People with Thalassaemia","volume":"8","author":"Bollig","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1345\/aph.1H338","article-title":"Impact of Residence on Prevalence and Intensity of Prescription Drug Use Among Older Adults","volume":"40","author":"Carrie","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/17474086.2018.1489719","article-title":"The Benefits of Prophylaxis in Patients with Hemophilia B","volume":"11","author":"Castaman","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13023-018-0840-4","article-title":"Effect of Carglumic Acid with or without Ammonia Scavengers on Hyperammonaemia in Acute Decompensation Episodes of Organic Acidurias","volume":"13","author":"Chakrapani","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3892\/etm.2013.971","article-title":"Long-term Effects of a Combination of D-Penicillamine and Zinc Salts in the Treatment of Wilson's Disease in Children","volume":"5","author":"Chang","year":"2013","journal-title":"Exp. Ther. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.12809\/hkmj134085","article-title":"Novel Use of Idebenone in Leber's Hereditary Optic Neuropathy in Hong Kong","volume":"20","author":"Cheng","year":"2014","journal-title":"Hong Kong Med. J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13023-021-01733-4","article-title":"Epidemiology of Systemic Sclerosis: a Multi-Database Population-Based Study in Tuscany (Italy)","volume":"16","author":"Coi","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000481358","article-title":"Prevalence Estimates of Rare Congenital Anomalies by Integrating Two Population-Based Registries in Tuscany, Italy","volume":"20","author":"Coi","year":"2017","journal-title":"Public Health Genomics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejps.2014.02.014","article-title":"Effect of Pirfenidone on Proliferation, TGF-\u03b2-Induced Myofibroblast Differentiation and Fibrogenic Activity of Primary Human Lung Fibroblasts","volume":"58","author":"Conte","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat Compared with Imiglucerase in Patients with Gaucher's Disease Type 1 Stabilised on Enzyme Replacement Therapy: a Phase 3, Randomised, Open-Label, Non-inferiority Trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.anai.2013.06.021","article-title":"Effect of Time to Treatment on Response to C1 Esterase Inhibitor Concentrate for Hereditary Angioedema Attacks","volume":"111","author":"Craig","year":"2013","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3389\/fpubh.2019.00416","article-title":"A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries","volume":"7","author":"Czech","year":"2020","journal-title":"Front. Public Health"},{"key":"B27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/ene.12348","article-title":"D-penicillamine versus Zinc Sulfate as First-Line Therapy for Wilson's Disease","volume":"21","author":"Cz\u0142onkowska","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"B28","unstructured":"Pharmaceutical Prescriptions in Umbria. Data Analysis for 2018 [in Italian]. Rapporti Istisan 20\/11\n            Da CasR.\n            RuggeriP.\n            IppolitiI.\n            TraversaG.\n            BucaneveG.\n            CasucciP.\n          2020"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1111\/bcp.13240","article-title":"Affordable Orphan Drugs: a Role for Not-for-profit Organizations","volume":"83","author":"Davies","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMoa042976","article-title":"High-dose Acetylcysteine in Idiopathic Pulmonary Fibrosis","volume":"353","author":"Demedts","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B31","unstructured":"The Orphan Drug Act \u2013 Implementation and Impact1983"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/14656566.2020.1751124","article-title":"Pharmacological Treatment Strategies for Subependymal Giant Cell Astrocytoma (SEGA)","volume":"21","author":"Ebrahimi-Fakhari","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"B33","unstructured":"Rapamune"},{"key":"B34","unstructured":"EU Research on Rare Diseases2020"},{"key":"B35","unstructured":"Ammonaps"},{"key":"B36","unstructured":"Rixubis"},{"key":"B37","unstructured":"Alprolix"},{"key":"B38","unstructured":"BeneFIX"},{"key":"B39","unstructured":"Galafold"},{"key":"B40","unstructured":"Idelvion"},{"key":"B41","unstructured":"Kuvan"},{"key":"B42","unstructured":"Market Exclusivity: Orphan Medicines2022"},{"key":"B43","unstructured":"Orphan Medicines Figures 2000-20202020"},{"key":"B44","unstructured":"Pheburane"},{"key":"B45","unstructured":"Votubia"},{"key":"B46","unstructured":"Zavesca"},{"key":"B47","unstructured":"Regulation (EC) N\u00b0141\/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products1999"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1016\/j.jaip.2020.02.043","article-title":"Clinical Characteristics and Safety of Plasma-Derived C1-Inhibitor Therapy in Children and Adolescents with Hereditary Angioedema-A Long-Term Survey","volume":"8","author":"Farkas","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.jaip.2017.04.010","article-title":"Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema","volume":"5","author":"Farkas","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B50","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/jimd.12370","article-title":"Guidelines for the Diagnosis and Management of Methylmalonic Acidaemia and Propionic Acidaemia: First Revision","volume":"44","author":"Forny","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.drudis.2012.08.009","article-title":"Orphan Drugs: the Regulatory Environment","volume":"18","author":"Franco","year":"2013","journal-title":"Drug Discov. Today"},{"key":"B52","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1183\/13993003.01032-2015","article-title":"2015 ESC\/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"46","author":"Gali\u00e8","year":"2015","journal-title":"Eur. Respir. J."},{"key":"B53","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/cge.13546","article-title":"Consensus Recommendations for Diagnosis, Management and Treatment of Fabry Disease in Paediatric Patients","volume":"96","author":"Germain","year":"2019","journal-title":"Clin. Genet."},{"key":"B54","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12664-018-0829-x","article-title":"Maintenance Zinc Therapy after Initial Penicillamine Chelation to Treat Symptomatic Hepatic Wilson's Disease in Resource Constrained Setting","volume":"37","author":"Gupta","year":"2018","journal-title":"Indian J. Gastroenterol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/jimd.12100","article-title":"Suggested Guidelines for the Diagnosis and Management of Urea Cycle Disorders: First Revision","volume":"42","author":"H\u00e4berle","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13023-018-0963-7","article-title":"Hyperammonaemia in Classic Organic Acidaemias: a Review of the Literature and Two Case Histories","volume":"13","author":"H\u00e4berle","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1586\/17476348.2015.1106316","article-title":"Riociguat for the Treatment of Pulmonary Hypertension","volume":"9","author":"Hambly","year":"2015","journal-title":"Expert Rev. Respir. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/CE.S20201","article-title":"An Evidence-Based Review of the Potential Benefits of Taliglucerase Alfa in the Treatment of Patients with Gaucher Disease","volume":"7","author":"Hollak","year":"2012","journal-title":"Core Evid."},{"key":"B59","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1124\/jpet.108.142976","article-title":"Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist","volume":"327","author":"Iglarz","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B60","unstructured":"Medicines Use in Italy, National Report Year 20202020"},{"key":"B61","unstructured":"Orphan Medicinal Products2022"},{"key":"B62","unstructured":"Orphan Medicines Lists December 31, 20182018"},{"key":"B63","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/ane.12572","article-title":"Rufinamide in Children and Adults in Routine Clinical Practice","volume":"135","author":"Jaraba","year":"2017","journal-title":"Acta Neurol. Scand."},{"key":"B64","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1007\/s12325-019-01113-2","article-title":"Leber's Hereditary Optic Neuropathy as a Promising Disease for Gene Therapy Development","volume":"36","author":"Karaarslan","year":"2019","journal-title":"Adv. Ther."},{"key":"B65","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/ejh.13512","article-title":"Changing Patterns in the Epidemiology of \u03b2-thalassemia","volume":"105","author":"Kattamis","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40256-016-0188-x","article-title":"Macitentan: A Review in Pulmonary Arterial Hypertension","volume":"16","author":"Keating","year":"2016","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"B67","first-page":"A7396","article-title":"OPsumit\u00ae USers Registry (OPUS): Insights into the Safety and Tolerability of Opsumit\u00ae. Abstract Retrieved from American Thoracic Society International Conference Abstracts. (Abstract No. P1031)","volume":"193","author":"Kim","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2677e230","DOI":"10.1093\/brain\/awr17010.1093\/brain\/aws279","article-title":"A Randomized Placebo-Controlled Trial of Idebenone in Leber's Hereditary Optic neuropathyPersistence of the Treatment Effect of Idebenone in Leber's Hereditary Optic Neuropathy","volume":"134136","author":"Klopstock","year":"20112013","journal-title":"BrainBrain"},{"key":"B70","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/s0898-6568(03)00040-8","article-title":"Tumour Suppressors Hamartin and Tuberin: Intracellular Signalling","volume":"15","author":"Krymskaya","year":"2003","journal-title":"Cell Signal"},{"key":"B71","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40256-018-00324-2","article-title":"The Efficacy and Safety of Aerosolized Iloprost in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis","volume":"19","author":"Kuang","year":"2019","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e0075","DOI":"10.1097\/MD.0000000000010075","article-title":"The Efficiency of Endothelin Receptor Antagonist Bosentan for Pulmonary Arterial Hypertension Associated with Congenital Heart Disease: A Systematic Review and Meta-Analysis","volume":"97","author":"Kuang","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"B73","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0140-6736(07)61234-3","article-title":"Efficacy of Sapropterin Dihydrochloride (Tetrahydrobiopterin, 6R-BH4) for Reduction of Phenylalanine Concentration in Patients with Phenylketonuria: a Phase III Randomised Placebo-Controlled Study","volume":"370","author":"Levy","year":"2007","journal-title":"Lancet"},{"key":"B74","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13023-019-1012-x","article-title":"Efficacy and Safety of mTOR Inhibitors (Rapamycin and its Analogues) for Tuberous Sclerosis Complex: a Meta-Analysis","volume":"14","author":"Li","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"B75","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40265-019-01079-z","article-title":"Phenylketonuria: Current Treatments and Future Developments","volume":"79","author":"Lichter-Konecki","year":"2019","journal-title":"Drugs"},{"key":"B126","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jns.2015.06.010","article-title":"Early Neurological Worsening in Patients With Wilson\u2019s Disease","volume":"355","author":"Litwin","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.anai.2011.08.015","article-title":"Randomized Placebo-Controlled Trial of the Bradykinin B\u2082 Receptor Antagonist Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema: the FAST-3 Trial","volume":"107","author":"Lumry","year":"2011","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s13023-021-01932-z","article-title":"Everolimus versus Sirolimus for Angiomyolipoma Associated with Tuberous Sclerosis Complex: a Multi-Institutional Retrospective Study in China","volume":"16","author":"Luo","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40265-016-0574-3","article-title":"Idebenone: A Review in Leber's Hereditary Optic Neuropathy","volume":"76","author":"Lyseng-Williamson","year":"2016","journal-title":"Drugs"},{"key":"B79","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12931-019-1161-4","article-title":"Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis: Time to Treat","volume":"20","author":"Maher","year":"2019","journal-title":"Respir. Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/cei.12358","article-title":"Repeat Treatment of Acute Hereditary Angioedema Attacks with Open-Label Icatibant in the FAST-1 Trial","volume":"177","author":"Malbr\u00e1n","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.phoj.2017.10.003","article-title":"Management of SS-Thalassemia - Consensus and Controversies!","volume":"2","author":"Manglani","year":"2017","journal-title":"Pediatr. Hematol. Oncol. J."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1111\/trf.12501","article-title":"Pharmacokinetics of Plasma-Derived C1-Esterase Inhibitor after Subcutaneous versus Intravenous Administration in Subjects with Mild or Moderate Hereditary Angioedema: the PASSION Study","volume":"54","author":"Martinez-Saguer","year":"2014","journal-title":"Transfusion"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e53773","DOI":"10.1371\/journal.pone.0053773","article-title":"Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment","volume":"8","author":"Maurer","year":"2013","journal-title":"PLoS One"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1111\/all.13384","article-title":"The International WAO\/EAACI Guideline for the Management of Hereditary Angioedema-The 2017 Revision and Update","volume":"73","author":"Maurer","year":"2018","journal-title":"Allergy"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s12170-020-00663-3","article-title":"Management of Pulmonary Arterial Hypertension","volume":"15","author":"Mayeux","year":"2021","journal-title":"Curr. Cardiovasc. Risk Rep."},{"key":"B86","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","article-title":"Migalastat: A Review in Fabry Disease","volume":"79","author":"McCafferty","year":"2019","journal-title":"Drugs"},{"key":"B87","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40265-015-0363-4","article-title":"Eltrombopag: a Review of its Use in Patients with Severe Aplastic Anaemia","volume":"75","author":"McCormack","year":"2015","journal-title":"Drugs"},{"key":"B88","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40120-016-0041-9","article-title":"Treatment of Adults with Lennox-Gastaut Syndrome: Further Analysis of Efficacy and Safety\/Tolerability of Rufinamide","volume":"5","author":"McMurray","year":"2016","journal-title":"Neurol. Ther."},{"key":"B89","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrd3654","article-title":"Rare Diseases and Orphan Drugs","volume":"11","author":"Melnikova","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"B90","doi-asserted-by":"publisher","first-page":"129437","DOI":"10.1016\/j.bbagen.2019.129437","article-title":"Progress in the Understanding and Treatment of Fabry Disease","volume":"1864","author":"Miller","year":"2020","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"B91","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/MPG.0b013e31821d5abe","article-title":"Zinc Monotherapy from Time of Diagnosis for Young Pediatric Patients with Presymptomatic Wilson Disease","volume":"53","author":"Mizuochi","year":"2011","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"B92","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2147\/nedt.2006.2.4.475","article-title":"Psychopharmacology of Topiramate: from Epilepsy to Bipolar Disorder","volume":"2","author":"Mula","year":"2006","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"B93","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12887-019-1571-y","article-title":"Evaluation of Long-Term Effectiveness of the Use of Carglumic Acid in Patients with Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA): Study Protocol for a Randomized Controlled Trial","volume":"19","author":"Nashabat","year":"2019","journal-title":"BMC Pediatr."},{"key":"B94","unstructured":"Orphan Drugs in the United States: An Examination of Patents and Orphan Drug Exclusivity2021"},{"key":"B95","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","article-title":"Estimating Cumulative point Prevalence of Rare Diseases: Analysis of the Orphanet Database","volume":"28","author":"Nguengang Wakap","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2016.01.002","article-title":"Long-term Safety and Seizure Outcome in Japanese Patients with Lennox-Gastaut Syndrome Receiving Adjunctive Rufinamide Therapy: An Open-Label Study Following a Randomized Clinical Trial","volume":"121","author":"Ohtsuka","year":"2016","journal-title":"Epilepsy Res."},{"key":"B97","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/emmm.200900036","article-title":"Treating Lysosomal Storage Diseases with Pharmacological Chaperones: from Concept to Clinics","volume":"1","author":"Parenti","year":"2009","journal-title":"EMBO Mo.l Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.rmed.2008.03.018","article-title":"Interstitial Lung Diseases Network of the American College of Chest PhysiciansAssessment of Current Practice in the Diagnosis and Therapy of Idiopathic Pulmonary Fibrosis","volume":"102","author":"Peikert","year":"2008","journal-title":"Respir. Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1007\/s00417-019-04444-6","article-title":"Visual Function in Chronic Leber's Hereditary Optic Neuropathy during Idebenone Treatment Initiated 5 to 50 Years after Onset","volume":"257","author":"Pemp","year":"2019","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2147\/PPA.S136754","article-title":"Profile of Sodium Phenylbutyrate Granules for the Treatment of Urea-Cycle Disorders: Patient Perspectives","volume":"11","author":"Pe\u00f1a-Quintana","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"B101","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/14712598.2019.1595581","article-title":"Current and Emerging Biologics for the Treatment of Hereditary Angioedema","volume":"19","author":"Perego","year":"20192019","journal-title":"Expert Opin. Biol. Ther."},{"key":"B102","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11864-017-0511-z","article-title":"Diagnosis and Treatment of Aplastic Anemia","volume":"18","author":"Peslak","year":"2017","journal-title":"Curr. Treat. Options. Oncol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1056\/NEJMe1713735","article-title":"Closing in on Treatment for Hemophilia B","volume":"377","author":"Porteus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1002\/hep.22261","article-title":"American Association for Study of Liver Diseases (AASLD)Diagnosis and Treatment of Wilson Disease: an Update","volume":"47","author":"Roberts","year":"2008","journal-title":"Hepatology"},{"key":"B106","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2450\/2010.0011-10","article-title":"Italian Ad Hoc Study groupReplacement Therapy with Recombinant Factor IX. A Multicentre Evaluation of Current Dosing Practices in Italy","volume":"9","author":"Rocca","year":"2011","journal-title":"Blood Transfus."},{"key":"B107","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2450\/2014.0223-14","article-title":"Principles of Treatment and Update of Recommendations for the Management of Haemophilia and Congenital Bleeding Disorders in Italy","volume":"12","author":"Rocino","year":"2014","journal-title":"Blood Transfus."},{"key":"B108","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s40263-015-0281-8","article-title":"Antiepileptic Drug Treatment in Children with Epilepsy","volume":"29","author":"Rosati","year":"2015","journal-title":"CNS Drugs"},{"key":"B109","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/epi.13981","article-title":"Comparative Efficacy of Antiepileptic Drugs in Children and Adolescents: A Network Meta-Analysis","volume":"59","author":"Rosati","year":"2018","journal-title":"Epilepsia"},{"key":"B110","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1007\/s10072-020-05013-0","article-title":"Neurological Features and Outcomes of Wilson's Disease: a Single-center Experience","volume":"42","author":"Samanci","year":"2021","journal-title":"Neurol. Sci."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1517\/14712598.2013.819339","article-title":"Development of Long-Acting Recombinant FVIII and FIX Fc Fusion Proteins for the Management of Hemophilia","volume":"13","author":"Shapiro","year":"2013","journal-title":"Expert Opin. Biol. Ther."},{"key":"B112","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13023-020-01639-7","article-title":"Assessing Rare Diseases Prevalence Using Literature Quantification","volume":"16","author":"Shourick","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"B113","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1183\/09059180.00004812","article-title":"Pathways in Pulmonary Arterial Hypertension: the Future Is Here","volume":"21","author":"Sitbon","year":"2012","journal-title":"Eur. Respir. Rev."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd Edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"B115","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1750-1172-4-27","article-title":"No Difference in Between-Country Variability in Use of Newly Approved Orphan and Non- Orphan Medicinal Products-Aa Pilot Study","volume":"4","author":"Stolk","year":"2009","journal-title":"Orphanet J. Rare Dis."},{"key":"B116","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1684\/epd.2017.0950","article-title":"Rufinamide for the Treatment of Lennox-Gastaut Syndrome: Evidence from Clinical Trials and Clinical Practice","volume":"20","author":"Striano","year":"2018","journal-title":"Epileptic Disord."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","article-title":"Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia","volume":"376","author":"Townsley","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jpeds.2008.11.040","article-title":"Efficacy of Sapropterin Dihydrochloride in Increasing Phenylalanine Tolerance in Children with Phenylketonuria: a Phase III, Randomized, Double-Blind, Placebo-Controlled Study","volume":"154","author":"Trefz","year":"2009","journal-title":"J. Pediatr."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/ajh.24479","article-title":"Deferiprone-induced Agranulocytosis: 20 Years of Clinical Observations","volume":"91","author":"Tricta","year":"2016","journal-title":"Am. J. Hematol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13023-016-0406-2","article-title":"Carglumic Acid Enhances Rapid Ammonia Detoxification in Classical Organic Acidurias with a Favourable Risk-Benefit Profile: a Retrospective Observational Study","volume":"11","author":"Valayannopoulos","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"B121","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(16)30320-5","article-title":"Key European Guidelines for the Diagnosis and Management of Patients with Phenylketonuria","volume":"5","author":"van Spronsen","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.seizure.2018.10.016","article-title":"The Pharmacological Management of Lennox-Gastaut Syndrome and Critical Literature Review","volume":"63","author":"Verrotti","year":"2018","journal-title":"Seizure"},{"key":"B123","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.rmed.2014.01.003","article-title":"Efficacy and Safety of Sildenafil Treatment in Pulmonary Arterial Hypertension: a Systematic Review","volume":"108","author":"Wang","year":"2014","journal-title":"Respir. Med."},{"key":"B124","doi-asserted-by":"publisher","first-page":"e82662","DOI":"10.1371\/journal.pone.0082662","article-title":"Comparative Efficacy and Safety of Deferoxamine, Deferiprone and Deferasirox on Severe Thalassemia: a Meta-Analysis of 16 Randomized Controlled Trials","volume":"8","author":"Xia","year":"2013","journal-title":"PLoS One"},{"key":"B125","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12931-019-0977-2","article-title":"Effect of Pirfenidone on Lung Function Decline and Survival: 5-yr Experience from a Real-Life IPF Cohort from the Czech EMPIRE Registry","volume":"20","author":"Zurkova","year":"2019","journal-title":"Respir. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.869842\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T04:44:11Z","timestamp":1652676251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.869842\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":126,"alternative-id":["10.3389\/fphar.2022.869842"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.869842","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"article-number":"869842"}}